Navigation Links
Georgetown physician leads national resveratrol study for Alzheimer's disease
Date:5/13/2012

WASHINGTON A national, phase II clinical trial examining the effects of resveratrol on individuals with mild to moderate dementia due to Alzheimer's disease has begun as more than two dozen academic institutions recruit volunteers in the coming months. R. Scott Turner, M.D., Ph.D., director of Georgetown University Medical Center's Memory Disorders Program, is the lead investigator for the national study.

Resveratrol is a compound found in red grapes, red grape juice, red wine, chocolate, tomatoes and peanuts. Pre-clinical and pilot clinical research studies suggest that resveratrol may prevent diabetes, act as a natural cancer fighter, ward off cardiovascular disease, and prevent memory loss, but there has been no large definitive study of its effects in humans.

The risk of all of these diseases increases with aging. Animal studies suggest that resveratrol may impede molecular mechanisms of aging. Human population studies suggest several health benefits from modest daily consumption of red wine, but the mechanisms of action in the body are unknown.

"Most resveratrol studies showing any health benefits have been conducted in animal models, such as mice, and with doses that far exceed intake from sipping wine or nibbling on chocolate," says Turner. "With this clinical trial, we'll find out if daily doses of pure resveratrol can delay or alter memory deterioration and daily functioning in people with mild to moderate dementia due to Alzheimer's."

"During this study, we will also test whether resveratrol improves glucose and insulin metabolism in older individuals -- although those who already have diabetes will not be included in this study."

Resveratrol is not approved by the Food and Drug Administration for the treatment of Alzheimer's. It is not known if resveratrol can change the course of the disease.

Not everyone who enrolls in the study will receive resveratrol. Half of the participants will receive a placebo (a sugar pill made to look like the resveratrol pill) to allow researchers to more objectively test the benefits of resveratrol. Neither the patient nor the clinical staff will know if the study participant is receiving the placebo or resveratrol until the end of the study.

"This is the gold-standard for conducting a clinical study because it allows us to objectively determine if resveratrol is offering any benefits," explains Brigid Reynolds, NP, lead investigator for the study at Georgetown.

In addition, the phase II study will examine the safety and tolerability of resveratrol administered twice daily with a dose increase planned at three-month intervals, she says.

According to the National Institute of Aging, more than 5.3 million people in the U.S. are suffering from Alzheimer's, and every 70 seconds, another person develops this disease. In Washington, DC, more than 9,000 people aged 65 and older are currently living with Alzheimer's.

The resveratrol study will be conducted at 26 U.S. academic institutions that are affiliated with the Alzheimer's Disease Cooperative Study. Patients who volunteer for the study cannot be enrolled in another clinical trial during the study period. They will also be asked to abstain from eating or drinking large quantities of foods or beverages that contain resveratrol, and abstain from taking dietary supplements containing resveratrol.

Each patient will be in the study for a twelve-month period and will require a study partner (spouse, friend or caregiver) to visit the Georgetown University Medical Center 10 times over the course of that year. Participants must be willing and able to undergo two lumbar punctures (a procedure where a needle is inserted into the lower spine to collect fluid), three MRI scans of the brain, and blood and urine tests during the course of the study.

The research is sponsored by the Alzheimer's Disease Cooperative Study (ADCS), through a grant from the National Institute on Aging (NIA). Turner and Reynolds report no personal financial interests related to the study.


'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
Georgetown University Medical Center
Source:Eurekalert

Related medicine news :

1. Georgetown University Center for Children and Families Hails Health Reform As Big Win for Children and Families
2. Georgetown Research Center Helps Reporters Decipher Health Reform Law & Impact on State Residents
3. FDA and Georgetown University Medical Center announce partnership
4. Georgetown research identifies key reasons racial disparities exist in emergent stroke treatment
5. FDA awards Georgetown University a Center of Excellence in Regulatory Science & Innovation
6. Georgetown researchers examine 21-year series of nipple sparing mastectomy cases and find no cancers
7. Georgetown professor applauds decision of researchers to temporarily halt research on H5N1
8. Georgetown University Medical Center licenses theranostic for development
9. Georgetown Lombardi researchers present new findings on head & neck cancers
10. MedPage Today(R) What Your Physicians Are Reading
11. The Case for the iPad: Mobile Charge Capture for Physicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... Amica Life Insurance Company ... life insurance throughout various life stages. , The site launched on April 1, ... and content specific to the times when life insurance matters most. , “Through ...
(Date:5/2/2016)... ... May 02, 2016 , ... The National Resident Matching Program® ... Match® (“the Match”), the system through which U.S. and international medical school students ... positions were placed in the 2016 Match, and 29,572 were filled when the ...
(Date:5/2/2016)... NY (PRWEB) , ... May 02, 2016 , ... Over ... the year’s best in pet gear and toys, leading product review site for Toys, ... Paw of Excellence Awards at their Spring Showcase at the Metropolitan Pavilion in ...
(Date:5/2/2016)... Rhinebeck, NY (PRWEB) , ... May 02, 2016 , ... ... Valley, reopened for its 2016 guest season which runs through October. Omega is offering ... talks . , “There has never been such widespread interest in or ...
(Date:5/2/2016)... ... ... Dr. Rassouli, dentist in Orange County, CA comments on the ... was published in the “Journal of the American Geriatrics Society,” more than a third ... Alzheimer’s disease. The study found that dental problems may increase the risk of heart ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 3, 2016 ... Research Report provides a basic overview of the ... post which the surgical mesh report explores into ... Complete report on Surgical Mesh market ... and 98 tables and figures is available at ...
(Date:5/3/2016)... 3, 2016 Norgine ... sie einen entscheidenden Meilenstein durch diese Veröffentlichung ... zum Handeln, um Patientenresultate  bei Verdauungs- und ... Fortschritten im Verständnis der Hepatischen Enzephalopathie bei ... für Hepatische Enzephalopathie in der Öffentlichkeit zu ...
(Date:5/2/2016)... , May 2, 2016 Kalorama Information noted ... Medical Records) market in a recent white paper.  The ... Increased physician usage, a growing market are among the ... in Kalorama,s report EMR 2016: The Market ... Kalorama,s seventh complete study of the EMR industry, and ...
Breaking Medicine Technology: